



## Caribou Biosciences to Participate in Upcoming Investor Conferences

May 31, 2023

BERKELEY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- [Caribou Biosciences, Inc.](#) (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, is scheduled to present at the following investor conferences during the month of June:

- Jefferies Healthcare Conference, New York, NY  
June 7, 2023, 3:00 pm EDT  
[Webcast](#)
- Goldman Sachs 44<sup>th</sup> Annual Global Healthcare Conference, Dana Point, CA  
June 13, 2023, 3:20 pm PDT  
[Webcast](#)

For more information, visit the [Events](#) page on Caribou's website. Webcasts will be available on the Caribou website for 30 days after the event.

### About Caribou's Novel Next-Generation CRISPR Platform

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems have exhibited editing at unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNA; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

### About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors. Follow us @CaribouBio and visit [www.cariboubio.com](http://www.cariboubio.com).

### Caribou Biosciences, Inc. Contacts:

#### Investors:

Amy Figueroa, CFA  
[investor.relations@cariboubio.com](mailto:investor.relations@cariboubio.com)

#### Media:

Peggy Vorwald, PhD  
[media@cariboubio.com](mailto:media@cariboubio.com)